Journal for Immunotherapy of Cancer
-
Publication Venue For
-
Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors..
9.
2021
-
SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery..
8.
2020
-
Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee..
8.
2020
-
Long-term survival of patients with stage III colon cancer treated with VRP-CEA(6D), an alphavirus vector that increases the CD8+ effector memory T cell to Treg ratio..
8.
2020
-
HER2-LAMP vaccines effectively traffic to endolysosomal compartments and generate enhanced polyfunctional T cell responses that induce complete tumor regression..
8.
2020
-
MRI of tumor T cell infiltration in response to checkpoint inhibitor therapy..
8.
2020
-
First in human dose calculation of a single-chain bispecific antibody targeting glioma using the MABEL approach..
8.
2020
-
Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma..
8.
2020
-
Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study..
8.
2020
-
Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer..
8.
2020
-
The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)..
7:354.
2019
-
Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential?.
7:325.
2019
-
Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies..
7:272.
2019
-
Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumors..
7:265.
2019
-
Combination immunotherapy and radiotherapy causes an abscopal treatment response in a mouse model of castration resistant prostate cancer..
7:218.
2019
-
Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations..
7:142.
2019
-
Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients..
7:104.
2019
-
Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry..
7:84.
2019
-
Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma..
7:80.
2019
-
Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients..
7:27.
2019
-
Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors..
7:18.
2019
-
Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial..
6:111.
2018
-
White paper on microbial anti-cancer therapy and prevention..
6:78.
2018
-
Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy..
6:77.
2018
-
Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy..
6:51.
2018
-
Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma..
6:9.
2018
-
Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond..
6:4.
2018
-
Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry..
5:102.
2017
-
Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor.
5.
2017
-
Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy..
5:44.
2017
-
A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma..
4:52.
2016
-
Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy..
4:89.
2016
-
Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials..
4:15.
2016
-
Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma..
4:44.
2016
-
Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial..
4:34.
2016
-
Combination of IFNα and poly-I:C reprograms bladder cancer microenvironment for enhanced CTL attraction..
3:6.
2015
-
Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review..
3:50.
2015
-
Phase I study of alphaviral vector (AVX701) in colorectal cancer patients: comparison of immune responses in stage III and stage IV patients.
3:P444-P444.
2015
-
Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis..
3:19.
2015
-
Targeting of phosphatidylserine by monoclonal antibodies augments the activity of paclitaxel and anti-PD1/PD-L1 therapy in the murine breast model E0771.
3:P357-P357.
2015
-
Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes..
2:20.
2014
-
Novel adenoviral serotype 5 based immunotherapeutic induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients.
1:P129-P129.
2013
-
A randomized multi-center phase 2 study of combined PD-L1/CTLA-4 inhibition with or without radiation in non-small cell lung cancer patients who progressed on PD-(L)1 directed therapy: ETCTN 10021
2019
-
A retrospective study to evaluate real-world clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with Ipilimumab and Nivolumab
2019
-
A tumor PD-L1-NLRP3 inflammasome signaling axis drives adaptive resistance to anti-PD-1 immunotherapy
2019
-
Combination cabozantinib and nivolumab treatment in patients with refractory metastatic renal cell carcinoma (mRCC)
2019
-
Utilization of second-line immuno-oncology agents and associated health outcomes among united states veterans with advanced non-small cell lung cancer
2019
-
A HSP-TLR-Wnt5a paracrine signaling axis drives CXCR2 ligand recruitment of myeloid-derived suppressor cells and represents a novel adaptive resistance mechanism to anti-PD-1 antibody therapy
2017
-
Chemotherapy enhances oncolytic recombinant poliovirus efficacy
2017
-
Generation of therapeutic RNAs to induce immunogenic cell death and interferon expression in cancer cells
2017
-
Microbiome analyses in patients with previously treated, deficient DNA mismatch repair/microsatellite instability-high metastatic colorectal cancer treated with nivolumab +/- ipilimumab: CheckMate 142
2017
-
PVSRIPO is an interferon-resistant, immunotherapeutic oncolytic virus
2017
-
Inflammasome-Wnt Ligand Signaling Axis Promotes Immune Escape During Anti-PD-1 Antibody Immunotherapy
-
The Wnt5a-β-catenin Pathway Triggers a Metabolic Switch That Drives Indoleamine 2,3-dioxygenase Activity and Dendritic Cell Tolerization in the Melanoma Microenvironment.